Mecobalamin

ApprovedSmall molecule

Eisai

Mecobalamin is one of 217 small molecule programs targeting Neurotoxicity. It is currently in Approved.

Indications

Total Trials

Active Trials

216

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeurotoxicityActive, not recruiting

Peripheral NeuropathyActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Facial ParalysisActive, not recruiting

DeafnessActive, not recruiting

Retinal Vein OcclusionActive, not recruiting

FibromyalgiaActive, not recruiting

DementiaActive, not recruiting

NeurotoxicityPhase 2/Phase 3

Active, not recruiting

Peripheral NeuropathyApproved

Active, not recruiting

Type 2 Diabetes MellitusPhase 2/Phase 3

Active, not recruiting

Facial ParalysisPreclinical

Active, not recruiting

DeafnessPreclinical

Active, not recruiting

Retinal Vein OcclusionApproved

Active, not recruiting

FibromyalgiaPhase 1/Phase 2

Active, not recruiting

DementiaApproved

Active, not recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Mecobalamin

Eisai

Approved

1 2

Byetta

AstraZeneca

Preclinical

20 3

Tanzeum

GSK

Preclinical

10 4

Insulin 320

Novo Nordisk

Preclinical

43 5

NOVOLIN R

Novo Nordisk

Preclinical

1 6

Adenocard

Astellas

Preclinical

1 7

Cipro

Lantus

6 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 10

Lixisenatide

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Neurovascular Coupling

NCT06813274

Q3 2027

Post-ApprovalRecruiting

Retinal Vein Occlusion

NCT07133438

Q4 2028

Phase 3Not yet recruiting

Recurrent Laryngeal Nerve

NCT07274696

Q2 2029

Phase 3Recruiting

Peripheral Neuropathy

NCT07423390

Clinical

Trials by Indication[1]

Peripheral Neuropathy4 trials

Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients

Unknown status·XXiangya Hospital of Central South University·Phase 4·NCT05184049·72 enrolled

Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy

Completed·—·Phase 4·NCT02923388·88 enrolled

Effect of Rotating Magnetic Therapy on Diabetic Peripheral Neuropathy

Unknown status·MMajianhua·N/A·NCT03983200·200 enrolled

Show 1 more trial

Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy

Recruiting·QQinghai Red Cross Hospital·Phase 3·NCT07423390·326 enrolled

Recurrent Laryngeal Nerve1 trial

Mecobalamin in Promoting Recurrent Laryngeal Nerve Function Recovery After Thyroid Surgery

Not yet recruiting·WWest China Hospital·Phase 3·NCT07274696·528 enrolled

Mesenchymal Stem Cell Transplantation1 trial

Autologous Adipose Mesenchymal Stem Cell Transplantation in the Treatment of Patients With Hemifacial Spasm

Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Phase 1·NCT02853942·100 enrolled

Neurotoxicity1 trial

Evaluate the Neuroprotective Effect of Vitamin B6 and Vitamin B12 Against Vincristine Induced Neurotoxicity in Acute Lymphoblastic Leukaemia Patients

Completed·—·Phase 2/3·NCT03593304·40 enrolled

Facial Paralysis1 trial

Effect of Stellate Ganglion Block Combined With Facial Nerve Block on the Treatment of Idiopathic Facial Paralysis

Completed·ZZhuan Zhang·N/A·NCT04800666·80 enrolled

9 more indications

Deafness1 trial

Effect of Ultrasound-guided Stellate Ganglion Block Combined With Facial Nerve and Glossopharyngeal Nerve Block on the Treatment of Sudden Deafness

Unknown status·ZZhuan Zhang·N/A·NCT05623384·90 enrolled

Neurovascular Coupling1 trial

Multicenter RCT of Eye-Brain Imaging in Diabetes Neurovascular Coupling

Not yet recruiting·HHejiang Ye·Phase 2·NCT06813274·160 enrolled

Fibromyalgia1 trial

Evaluation of the Efficiacy of Mecobalamine in the Treatment of Long-term Pain in Women Diagnosed With Fibromyalgia

Completed·LLinnaeus University·Phase 1/2·NCT05008042·40 enrolled

Active, not recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT05165069·234 enrolled

Injury1 trial

Mecobalamin Combined With Ceftriaxone Sodium in the Treatment of Sepsis Liver Injury

Unknown status·SSichuan Provincial People's Hospital·Phase 4·NCT06220929·40 enrolled

Dementia1 trial

The Role of Methycobalamin in Early Dementia Patients With Vitamin B12 Deficiency and Hyperhomocysteinaemia.

Completed· Eisai logo

Eisai·Phase 4·NCT00165711

Gastrectomy1 trial

Oral Vitamin B12 Administration for Vitamin B12 Deficiency After Total Gastrectomy

Completed·YYonsei University·Phase 2·NCT00699478·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Mecobalamin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mecobalamin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mecobalamin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Eisai

Mecobalamin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2028

Q2 2029

Trials by Indication[1]

Peripheral Neuropathy4 trials

Recurrent Laryngeal Nerve1 trial

Mesenchymal Stem Cell Transplantation1 trial

Neurotoxicity1 trial

Facial Paralysis1 trial

Deafness1 trial

Neurovascular Coupling1 trial

Fibromyalgia1 trial

Retinal Vein Occlusion1 trial

Type 2 Diabetes Mellitus1 trial

Efficacy and Safety1 trial

Injury1 trial

Dementia1 trial

Gastrectomy1 trial

References

Drug Info

Quick Facts

Related News